Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BYSINASDAQ:COCPNASDAQ:DTILNASDAQ:MIST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$3.11-8.5%$1.84$0.98▼$3.44$125.38M0.0729,274 shs213,609 shsCOCPCocrystal Pharma$1.55-2.5%$1.51$1.12▼$3.26N/A2.1526,677 shs13,161 shsDTILPrecision BioSciences$4.70-4.1%$5.05$3.61▼$11.09$52.12M1.48187,243 shs180,458 shsMISTMilestone Pharmaceuticals$1.72-0.6%$1.36$0.63▼$2.75$91.96M0.92932,153 shs562,341 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring0.00%+9.89%+85.01%+94.38%+9.51%COCPCocrystal Pharma0.00%+0.65%+2.31%-0.64%-37.75%DTILPrecision BioSciences0.00%-6.56%-3.69%-13.76%-53.47%MISTMilestone Pharmaceuticals0.00%+2.38%+23.74%-9.47%+23.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/ACOCPCocrystal Pharma1.7545 of 5 stars3.53.00.00.00.61.70.0DTILPrecision BioSciences4.0698 of 5 stars3.53.00.04.60.01.71.3MISTMilestone Pharmaceuticals2.0984 of 5 stars3.23.00.00.01.82.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBYSIBeyondSpring 0.00N/AN/AN/ACOCPCocrystal Pharma 3.00Buy$7.00351.61% UpsideDTILPrecision BioSciences 3.00Buy$47.00900.00% UpsideMISTMilestone Pharmaceuticals 2.40Hold$7.00306.98% UpsideCurrent Analyst Ratings BreakdownLatest COCP, DTIL, BYSI, and MIST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$5.005/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/1/2025MISTMilestone PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2025MISTMilestone PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/1/2025MISTMilestone PharmaceuticalsTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/28/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/28/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBYSIBeyondSpring$1.75M71.65N/AN/A($0.37) per share-8.41COCPCocrystal PharmaN/AN/AN/AN/A$0.94 per shareN/ADTILPrecision BioSciences$68.70M0.76N/AN/A$6.87 per share0.68MISTMilestone Pharmaceuticals$1M91.95N/AN/A$0.25 per share6.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/ACOCPCocrystal Pharma-$17.50M-$1.57N/AN/AN/AN/A-135.12%-102.38%8/13/2025 (Estimated)DTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)MISTMilestone Pharmaceuticals-$41.52M-$0.78N/AN/AN/AN/A-329.85%-67.20%8/7/2025 (Estimated)Latest COCP, DTIL, BYSI, and MIST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025COCPCocrystal Pharma-$0.52-$0.23+$0.29-$0.23N/AN/A5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/14/2025Q1 2025MISTMilestone Pharmaceuticals-$0.19-$0.31-$0.12-$0.31N/AN/A5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/A3/27/2025Q4 2024COCPCocrystal Pharma-$0.55-$0.32+$0.23-$0.32N/AN/A3/26/2025Q4 2024DTILPrecision BioSciences-$2.09-$3.20-$1.11-$2.22$4.28 million$3.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBYSIBeyondSpringN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBYSIBeyondSpringN/A2.492.49COCPCocrystal PharmaN/A4.574.57DTILPrecision BioSciences0.456.626.62MISTMilestone Pharmaceuticals4.064.674.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBYSIBeyondSpring40.29%COCPCocrystal Pharma6.72%DTILPrecision BioSciences37.99%MISTMilestone Pharmaceuticals86.18%Insider OwnershipCompanyInsider OwnershipBYSIBeyondSpring29.31%COCPCocrystal Pharma28.14%DTILPrecision BioSciences4.50%MISTMilestone Pharmaceuticals19.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBYSIBeyondSpring8040.32 million28.50 millionOptionableCOCPCocrystal Pharma10N/AN/ANot OptionableDTILPrecision BioSciences20011.09 million10.59 millionNo DataMISTMilestone Pharmaceuticals3053.46 million43.04 millionOptionableCOCP, DTIL, BYSI, and MIST HeadlinesRecent News About These CompaniesMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives $7.00 Average PT from AnalystsJune 19 at 1:29 AM | americanbankingnews.comMilestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A MeetingJune 17 at 12:40 AM | finance.yahoo.comMilestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A MeetingJune 16, 2025 | globenewswire.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from BrokeragesJune 16, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Milestone Pharmaceuticals (NASDAQ:MIST)June 5, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Sees Large Decrease in Short InterestJune 4, 2025 | marketbeat.comToronto Dominion Bank Buys New Stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)June 1, 2025 | marketbeat.comMilestone Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comToronto Dominion Bank Makes New Investment in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)May 26, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Recommendation of "Hold" from AnalystsMay 24, 2025 | marketbeat.comMilestone Pharmaceuticals (MIST) Upgraded to Buy: Here's WhyMay 22, 2025 | zacks.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Stonepine Capital Management LLCMay 20, 2025 | marketbeat.comMilestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateMay 15, 2025 | finanznachrichten.deMilestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateMay 14, 2025 | globenewswire.comMilestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVTApril 9, 2025 | seekingalpha.comMIST Stock Falls 66% Following Complete Response Letter for CardamystApril 2, 2025 | zacks.comMilestone Pharmaceuticals price target lowered to $10 from $25 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comTD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertaintyApril 2, 2025 | finance.yahoo.comMilestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD CowenApril 2, 2025 | markets.businessinsider.comMilestone Pharmaceuticals Shares Hit New Low After FDA Rejects EtripamilMarch 29, 2025 | marketwatch.comMilestone Stock Crashes After Surprise Tachycardia Drug RejectionMarch 29, 2025 | biospace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOCP, DTIL, BYSI, and MIST Company DescriptionsBeyondSpring NASDAQ:BYSI$3.11 -0.29 (-8.53%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$3.07 -0.04 (-1.29%) As of 06/18/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Cocrystal Pharma NASDAQ:COCP$1.55 -0.04 (-2.52%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.60 +0.05 (+3.48%) As of 06/18/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Precision BioSciences NASDAQ:DTIL$4.70 -0.20 (-4.08%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$4.86 +0.16 (+3.30%) As of 06/18/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Milestone Pharmaceuticals NASDAQ:MIST$1.72 -0.01 (-0.58%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.72 0.00 (0.00%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
